drugset / Trial / NCT02322749

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

NCT02322749

Phase 1 Completed 48 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

A Study to assess, against a reference selumetinib capsule, if the drug levels of a variant of selumetinib capsule are comparable, and to assess how drug levels differed in another variant of Selumetinib in Healthy Male Volunteers.

Timeline

Start
2015-02
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Selumetinib Small molecule 75 mg Oral

Indications

No indication recorded.